Wenting Xu MD , Hanyue Dong MD , Haolong Ran MD , Huan Liu MD , Lin Wang MD , Hongmin Li MD, PhD , Cheng Tan MD, PhD
{"title":"Efficacy and Safety of Pregabalin and Gabapentin for Pruritus: A Systematic Review and Meta-Analysis","authors":"Wenting Xu MD , Hanyue Dong MD , Haolong Ran MD , Huan Liu MD , Lin Wang MD , Hongmin Li MD, PhD , Cheng Tan MD, PhD","doi":"10.1016/j.jpainsymman.2024.08.028","DOIUrl":null,"url":null,"abstract":"<div><h3>Context</h3><div>Limited data existed on the efficacy and safety of novel antiepileptic drugs (pregabalin and gabapentin) in treating pruritus.</div></div><div><h3>Objectives</h3><div>To assess their role in managing either acute or chronic pruritus.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science databases for relevant randomized controlled trials. Pooled odd ratio (OR) with 95% CI were performed using RevMan5.4 and R4.3.1.</div></div><div><h3>Results</h3><div>Analysis of 27 articles involving 2,016 patients showed significant reduction in pruritus incidence (OR, 0.30 [CI, 0.22–0.4]; I<sup>2</sup>=1%) and improvements in VAS (MD, 2.76 [CI, 0.95–4.57]; I<sup>2</sup>=98%) and 5-D scores (MD, 3.42 [CI, 2.10–4.75]; I<sup>2</sup>=92%) with pregabalin/gabapentin compared to controls. Adverse effects mainly included dizziness, somnolence, nausea and vomiting, dry mouth, constipation, and anxiety, with no significant difference between the groups (OR, 1.08 [CI, 0.32–3.59]; I<sup>2</sup>=76%).</div></div><div><h3>Conclusion</h3><div>The novel antiepileptic drugs pregabalin and gabapentin demonstrated significant therapeutic value in the treatment of pruritus, with a favorable safety profile. Compared to commonly used pruritus treatments such as antihistamines and antidepressants, these medications offered a promising alternative.</div></div>","PeriodicalId":16634,"journal":{"name":"Journal of pain and symptom management","volume":"69 1","pages":"Pages 65-81"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pain and symptom management","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0885392424009618","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Context
Limited data existed on the efficacy and safety of novel antiepileptic drugs (pregabalin and gabapentin) in treating pruritus.
Objectives
To assess their role in managing either acute or chronic pruritus.
Methods
A systematic search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science databases for relevant randomized controlled trials. Pooled odd ratio (OR) with 95% CI were performed using RevMan5.4 and R4.3.1.
Results
Analysis of 27 articles involving 2,016 patients showed significant reduction in pruritus incidence (OR, 0.30 [CI, 0.22–0.4]; I2=1%) and improvements in VAS (MD, 2.76 [CI, 0.95–4.57]; I2=98%) and 5-D scores (MD, 3.42 [CI, 2.10–4.75]; I2=92%) with pregabalin/gabapentin compared to controls. Adverse effects mainly included dizziness, somnolence, nausea and vomiting, dry mouth, constipation, and anxiety, with no significant difference between the groups (OR, 1.08 [CI, 0.32–3.59]; I2=76%).
Conclusion
The novel antiepileptic drugs pregabalin and gabapentin demonstrated significant therapeutic value in the treatment of pruritus, with a favorable safety profile. Compared to commonly used pruritus treatments such as antihistamines and antidepressants, these medications offered a promising alternative.
期刊介绍:
The Journal of Pain and Symptom Management is an internationally respected, peer-reviewed journal and serves an interdisciplinary audience of professionals by providing a forum for the publication of the latest clinical research and best practices related to the relief of illness burden among patients afflicted with serious or life-threatening illness.